Questions About Cancer? 1-800-4-CANCER

Late Effects of Treatment for Childhood Cancer (PDQ®)

Health Professional Version

Late Effects of the Central Nervous System

Neurocognitive

Neurocognitive late effects are most commonly observed after treatment of malignancies that require central nervous system (CNS)–directed therapies. CNS-directed therapies include the following:

  • Cranial radiation.
  • Systemic therapy with high-dose methotrexate or cytarabine.
  • Intrathecal chemotherapy.

Children with brain tumors or acute lymphoblastic leukemia (ALL) are most likely to be affected. Risk factors for the development of neurocognitive late effects include the following:[1-6]

  • Female gender.
  • Younger age at the time of treatment.
  • Tumor location.
  • Higher cranial radiation dose.
  • Treatment with both cranial radiation and chemotherapy (systemic or intrathecal).
  • Lower socioeconomic status.

It should be noted that the cognitive phenotypes observed in childhood survivors of ALL and CNS tumors may differ from traditional developmental disorders. For example, the phenotype of attention problems in ALL and brain tumor survivors appears to differ from developmental attention-deficit/hyperactivity disorder in that few survivors demonstrate significant hyperactivity/impulsivity, but instead have associated difficulties with processing speed and executive function.[7,8]

Neuroimaging studies of irradiated and nonirradiated ALL survivors demonstrate a variety of CNS abnormalities, including leukoencephalopathy, cerebral lacunes, cerebral atrophy, and dystrophic calcifications (mineralizing microangiopathy). Among these, abnormalities of cerebral white matter integrity and volume have been correlated with neurocognitive outcomes.[9]

Neurocognitive outcomes in brain tumor survivors

Survival rates have increased over recent decades for children with brain tumors; however, long-term cognitive effects caused by illness and associated treatments are a well-established morbidity in this group of survivors. In childhood and adolescent brain tumor survivors, risk factors for adverse neurocognitive effects include the following:

  • Cranial radiation therapy. Cranial radiation therapy has been associated with the highest risk of long-term cognitive morbidity, particularly in younger children.[10] There is an established dose-response relationship, with patients who receive higher-dose cranial radiation therapy consistently performing more poorly on intellectual measures.[11]
  • Tumor site.[10]
  • Shunted hydrocephalus.[10,12,13]
  • Postsurgical cerebellar mutism.[14]
  • Auditory difficulties.[12]
  • History of stroke.[15]

The negative impact of radiation treatment has been characterized by changes in intelligence quotient (IQ) scores, which have been noted to drop about 2 to 5 years after diagnosis; the decline continues 5 to 10 years afterward, although less is known about potential stabilization or further decline of IQ scores several decades after diagnosis.[16-18] The decline in IQ scores over time typically reflects the child’s failure to acquire new abilities or information at a rate similar to that of his or her peers, rather than a progressive loss of skills and knowledge.[11] Affected children also may experience deficits in other cognitive areas, including academic difficulties (reading and math) and problems with attention, processing speed, memory, and visual or perceptual motor skills.[17,19,20]

These changes in cognitive functioning may be partially explained by radiation-induced reduction of normal-appearing white matter volume or integrity of white matter pathways, as evaluated through magnetic resonance imaging (MRI).[21-24] In fact, reduced white matter integrity has been directly linked to slowed cognitive processing speed in survivors of brain tumors,[25] while greater white matter volume has been associated with better working memory, particularly in females.[24] It should be noted that data emerging from contemporary protocols show that using lower doses of cranial radiation and more targeted treatment volumes appears to reduce the severity of neurocognitive effects of therapy.[13,26]

Longitudinal cohort studies have provided insight into the trajectory and predictors of cognitive decline among survivors of CNS tumors. Results of representative cohort studies include the following:

  • A report from St. Jude Children’s Research Hospital showed cognitive decline after 54 Gy of conformal cranial radiation therapy in 78 children younger than 20 years (mean, 9.7 years) diagnosed with low-grade glioma (refer to Figure 3). Age at time of cranial radiation was more important than was cranial radiation dose in predicting cognitive decline, with children younger than 5 years estimated to experience the greatest cognitive decline.[27]

    Graph shows modeled IQ scores after conformal radiation therapy, by age measured in years, and time measured in months, after the start of CRT for pediatric low-grade glioma.
    Figure 3. Modeled intelligence quotient (IQ) scores after conformal radiation therapy (CRT) by age for pediatric low-grade glioma. Age is measured in years, and time is measured in months after the start of CRT.[27] Thomas E. Merchant, Heather M. Conklin, Shengjie Wu, Robert H. Lustig, and Xiaoping Xiong, Late Effects of Conformal Radiation Therapy for Pediatric Patients With Low-Grade Glioma: Prospective Evaluation of Cognitive, Endocrine, and Hearing Deficits, Journal of Clinical Oncology, volume 27, issue 22, pages 3691-3697. Reprinted with permission. © (2009) American Society of Clinical Oncology. All rights reserved.


  • In a study of 126 medulloblastoma survivors treated with 23.4 Gy or 36 Gy to 39.6 Gy of cranial spinal radiation (with a conformal boost dose of 55.8 Gy to the primary tumor bed), processing speed scores declined significantly over time, while less decline was observed in attention and memory performance. Higher doses of radiation and younger age at diagnosis predicted slower processing speed over time.[28] Studies of working memory and academic achievement in patients enrolled on the same medulloblastoma trial (St. Jude SJMB03 [NCT00085202]) indicated that performance was largely within the age-expected range up to 5 years postdiagnosis,[29,30] although in both studies, posterior fossa syndrome, higher cranial radiation dose, and younger age at diagnosis predicted worse performance over time. In addition, serious hearing loss was associated with intellectual and academic decline over time.[30]

Although adverse neurocognitive outcomes observed 5 to 10 years after treatment are presumed to be pervasive, and potentially worsen over time, few empirical data are available regarding the neurocognitive functioning in very long-term survivors of CNS tumors.

  • Among adult survivors participating in the Childhood Cancer Survivor Study (CCSS), CNS tumor survivors (n = 802) reported significantly more problems with attention/processing speed, memory, emotional control, and organization than did survivors of non-CNS malignancies (n = 5,937) and sibling controls (n = 382).[4] Moreover, a large proportion of CNS tumor survivors treated with cranial radiation reported impairment on measures of attention/processing speed (42.9%–73.3%) and memory (14.3%–37.4%), with differences observed by diagnosis and cranial radiation dose.[31]

The neurocognitive consequences of CNS disease and treatment may have a considerable impact on functional outcomes for brain tumor survivors.

  • In childhood and adolescence, neurocognitive deficits have been associated with poor social adjustment, including problems with peer relations, social withdrawal, and reduced social skills.[32,33]
  • CNS tumor survivors are more likely to need special education services than are survivors of other malignancies.[34]
  • Adult CNS tumor survivors are less likely to live independently, marry, and graduate from college than are survivors of other malignancies and siblings.[34-36]

Neurocognitive outcomes in acute lymphoblastic leukemia (ALL) survivors

The increase in cure rates for children with ALL over the past decades has resulted in greater attention to the neurocognitive morbidity and quality of life of survivors. The goal of current ALL treatment is to minimize adverse late effects while maintaining high survival rates. To minimize the risk of late sequelae, patients are stratified for treatment according to their risk of relapse. Cranial radiation is reserved for the fewer than 20% of children who are considered at high risk for CNS relapse.[37]

Although low-risk, standard-risk, and most high-risk patients are treated with chemotherapy-only protocols, early reports of neurocognitive late effects for ALL patients were based on heterogeneously treated groups of survivors who were treated with combinations (simultaneously or sequentially) of intrathecal chemotherapy, radiation, and high-dose chemotherapy, making it difficult to differentiate the impact of the individual treatment components. However, outcome data are increasingly available regarding the risk of neurocognitive late effects in survivors of childhood ALL treated with chemotherapy only.

ALL and cranial radiation

In survivors of ALL, cranial radiation therapy may result in clinical and radiographic neurologic late sequelae. Clinical leukoencephalopathy characterized by spasticity, ataxia, dysarthria, dysphagia, hemiparesis, and seizures is uncommon after contemporary ALL therapy. In contrast, neuroimaging frequently demonstrates white matter abnormalities among survivors treated with cranial irradiation and/or high-dose methotrexate. Radiographic leukoencephalopathy has been reported in up to 80% of children on some treatment regimens. Higher doses and more courses of intravenous methotrexate have been reported to increase risk of leukoencephalopathy.[9] In many patients, white matter anomalies are transient and decrease in prevalence, extent, and intensity with longer elapsed time from completion of therapy.[9] Leukoencephalopathy results in smaller white matter volumes that have been correlated with cognitive deficits. Although these abnormalities are mild among the irradiated patients (overall IQ fall of approximately 10 points), those who have received higher doses at a young age may have significant learning difficulties.[38,39] Deficits in neuropsychological functions such as visual-motor integration, processing speed, attention, and short-term memory are reported in children treated with 18 Gy to 24 Gy.[38,40,41] Girls and children treated at a younger age are more vulnerable to cranial radiation.[42] The decline in intellectual functioning appears to be progressive, showing more impairment of cognitive function with increasing time since radiation therapy.[42]

ALL and chemotherapy-only CNS therapy

Because of its penetrance into the CNS, systemic methotrexate has been used in a variety of low-dose and high-dose regimens for leukemia CNS prophylaxis. Systemic methotrexate in high doses with or without radiation therapy can lead to an infrequent but well-described leukoencephalopathy, which has been linked to neurocognitive impairment.[9] When neurocognitive outcomes after radiation therapy and chemotherapy-only regimens are directly compared, the evidence suggests a better outcome for those treated with chemotherapy alone, although some studies show no significant difference.[43,44]

Compared with cranial irradiation, chemotherapy-only CNS-directed treatment produces neurocognitive deficits involving processes of attention, speed of information processing, memory, verbal comprehension, visual-spatial skills, visual-motor functioning, and executive functioning; global intellectual function is typically preserved.[40,43,45,46] Few longitudinal studies evaluating long-term neurocognitive outcome report adequate data for a decline in global IQ after treatment with chemotherapy alone.[46] The academic achievement of ALL survivors in the long term seems to be generally average for reading and spelling, with deficits mainly affecting arithmetic performance.[43,47,48] Risk factors for poor neurocognitive outcome after chemotherapy-only CNS-directed treatment are younger age and female gender.[49,50]

Studies of neurocognitive functioning in large pediatric cancer survivor cohorts observed the following:

  • In the St. Jude Total XV (NCT00137111) trial, which omitted prophylactic cranial irradiation, comprehensive cognitive testing of 243 participants at week 120 revealed higher risk for below-average performance on a measure of sustained attention but not on measures of intellectual functioning, academic skills, or memory. The risk of cognitive deficits correlated with treatment intensity but not with age at diagnosis or gender. These results underscore the need for longitudinal follow-up to better characterize the prevalence and magnitude of cognitive deficits after CNS-directed therapy with chemotherapy alone.[51]
  • In a large prospective study (N = 555) of neurocognitive outcomes in children with newly diagnosed ALL who were randomly assigned to receive CNS-directed therapy according to risk group (low risk: intrathecal methotrexate vs. high-dose methotrexate; high risk: high-dose methotrexate vs. 24 Gy cranial radiation therapy), a significant reduction in IQ scores (4–7 points) was observed in all patient groups when compared with controls, regardless of the CNS treatment delivered. Children younger than 5 years at diagnosis were more likely to have IQs below 80 at 3 years posttherapy than were children older than 5 years at diagnosis, irrespective of treatment allocation, suggesting that younger children are more vulnerable to treatment-related neurologic toxic effects.[52]
  • Persistent cognitive deficits and progressive intellectual decline have been observed in cohorts of adults treated for ALL during childhood and associated with reduced educational attainment and unemployment.[39,42,53] According to the results of neurocognitive testing and patient reported outcomes in more than 500 adult survivors of childhood ALL at 26 years postdiagnosis, survivors demonstrated increased rates of impairment in most neurocognitive and behavioral domains. Impairment was common in survivors treated with lower doses of cranial radiation and in those treated with chemotherapy only. Impairment in executive function skills increased with time since diagnosis; impairment in intellect, academics, and memory progressively increased with younger age at treatment in a cranial radiation dose-dependent manner; and neurocognitive function was related to functional outcomes as adults, including college graduation and full-time employment. Continued monitoring by health professionals is recommended to identify neurocognitive problems that may emerge over time.[39]
ALL and steroid therapy

The type of steroid used for ALL systemic treatment may affect cognitive functioning. In a study that involved long-term neurocognitive testing (mean follow-up, 9.8 years) in 92 children with a history of standard-risk ALL who had received either dexamethasone or prednisone during treatment, no meaningful differences in cognitive functioning based on corticosteroid randomization were observed.[54] In contrast, in a study of 567 adult survivors of childhood leukemia (mean age, 33 years; mean time since diagnosis, 26 years) dexamethasone exposure was associated with increased risk of impairment in attention (relative risk [RR], 2.12; 95% confidence interval [CI], 1.11–4.03) and executive function (RR, 2.42; 95% CI, 1.20–4.91), independent of methotrexate exposure. Intrathecal hydrocortisone also increased risk of attention problems (RR, 1.24; 95% CI, 1.05–1.46).[39]

Other cancers

Neurocognitive abnormalities have been reported in other groups of cancer survivors. In a study of adult survivors of childhood non-CNS cancers (including ALL, n = 5,937), 13% to 21% of survivors reported impairment in task efficiency, organization, memory, or emotional regulation. This rate of impairment was approximately 50% higher than that reported in the sibling comparison group. Factors such as diagnosis before age 6 years, female gender, cranial radiation therapy, and hearing impediment were associated with impairment.[41]

Stem cell transplantation

Cognitive and academic consequences of stem cell transplantation in children have also been evaluated and include the following:

  • In a report from St. Jude Children’s Research Hospital in which 268 patients were treated with stem cell transplantation, minimal risk of late cognitive and academic sequelae was observed. Subgroups of patients were at relatively higher risk, including patients who underwent unrelated donor transplantation, received total-body radiation, and developed graft-versus-host disease (GVHD). However, these differences were small relative to differences in premorbid functioning, particularly those associated with socioeconomic status.[55]
  • In a series of 38 patients who underwent hematopoietic stem cell transplantation (HSCT) and received intrathecal chemotherapy, significant declines in visual motor skills and memory scores were noted within the first year posttransplant. By 3 years posttransplant, there was an improvement in visual motor development scores and memory scores, but new deficits were evident in long-term memory scores. By 5 years posttransplant, there were progressive declines in verbal skills and performance skills, and new deficits were seen in long-term verbal memory scores. The greatest decline in neurocognitive function occurred in patients who received cranial radiation, either as part of their initial therapy or as part of their HSCT conditioning.[56]

Most neurocognitive late effects after stem cell transplantation are thought to be related to white matter damage in the brain. This was investigated in children with leukemia who were treated with HSCT. In a series of 36 patients, performance on neurocognitive measures typically associated with white matter was compared with performance on measures thought to correlate with gray matter function. Composite white matter scores were significantly lower than composite gray matter scores, thereby supporting the belief that white matter damage contributes to neurocognitive late effects in this population.[57]

Neurologic Sequelae

Risk of neurologic complications may be predisposed by the following:

  • Tumor location.
  • Neurosurgery.
  • Cranial radiation therapy.
  • Specific neurotoxic chemotherapeutic agents.

In children with CNS tumors, mass effect, tumor infiltration, and increased intracranial pressure may result in motor or sensory deficits, cerebellar dysfunction, and secondary effects such as seizures and cerebrovascular complications.

Neurologic complications that may occur in adult survivors of childhood cancer include the following:

  • Leukoencephalopathy. Clinical or radiographic leukoencephalopathy has been reported after cranial radiation and high-dose systemic methotrexate administration. Younger patients and those treated with cranial radiation doses higher than 24 Gy are more vulnerable to reduced white matter volumes associated with leukoencephalopathy.[9,40] White matter changes may be accompanied by other neuroimaging abnormalities, including dystrophic calcifications, cerebral lacunae, and cerebral atrophy.
  • Peripheral neuropathy. Vinca alkaloid agents (vincristine and vinblastine) and cisplatin may cause peripheral neuropathy. This condition presents during treatment and appears to clinically resolve after completion of therapy. However, higher cumulative doses of vincristine and/or intrathecal methotrexate have been linked to neuromuscular impairments in long-term survivors of childhood ALL, which suggests that persistent effects of these agents may affect functional status in aging survivors.[58]

    Among adult survivors of extracranial solid tumors of childhood (median time from diagnosis, 25 years), standardized assessment of neuromuscular function disclosed motor impairment in association with vincristine exposure and sensory impairment in association with cisplatin exposure.[59] Survivors with sensory impairment demonstrated a higher prevalence of functional performance limitations related to poor endurance and mobility restrictions. These studies underscore the importance of assessment and referral to rehabilitative services to optimize functional outcomes among long-term survivors.

  • Stroke. Refer to the Vascular Disease/Cerebrovascular Accident section of this summary for information on stroke.
  • Other neurologic sequelae. In a report from the CCSS that compared 4,151 adult survivors of childhood ALL with siblings, survivors were at elevated risk for late-onset coordination problems, motor problems, seizures, and headaches. The overall cumulative incidence was 44% at 20 years. Serious headaches were most common, with a cumulative incidence of 25.8% at 20 years, followed by focal neurologic dysfunction (21.2%) and seizures (7%). Children who were treated with regimens that included cranial radiation for ALL and those who suffered relapse were at increased risk for late-onset neurologic sequelae.[60]
Table 3. Central Nervous System Late Effects
Predisposing TherapyNeurologic EffectsHealth Screening
IQ = intelligence quotient; IT = intrathecal; IV = intravenous.
Platinum agents (carboplatin, cisplatin)Peripheral sensory neuropathyNeurologic exam
Plant alkaloid agents (vinblastine, vincristine)Peripheral sensory or motor neuropathy (areflexia, weakness, foot drop, paresthesias)Neurologic exam
Methotrexate (high dose IV or IT); cytarabine (high dose IV or IT); radiation impacting the brainClinical leukoencephalopathy (spasticity, ataxia, dysarthria, dysphagia, hemiparesis, seizures); headaches; seizures; sensory deficitsHistory: cognitive, motor, and/or sensory deficits, seizures
Neurologic exam
Radiation impacting cerebrovascular structuresCerebrovascular complications (stroke, moyamoya, occlusive cerebral vasculopathy)History: transient/permanent neurological events
Blood pressure
Neurologic exam
Neurosurgery–brainMotor and/or sensory deficits (paralysis, movement disorders, ataxia, eye problems [ocular nerve palsy, gaze paresis, nystagmus, papilledema, optic atrophy]); seizuresNeurologic exam
Neurology evaluation
Neurosurgery–brainHydrocephalus; shunt malfunctionAbdominal x-ray
Neurosurgery evaluation
Neurosurgery–spineNeurogenic bladder; urinary incontinenceHistory: hematuria, urinary urgency/frequency, urinary incontinence/retention, dysuria, nocturia, abnormal urinary stream
Neurosurgery–spineNeurogenic bowel; fecal incontinenceHistory: chronic constipation, fecal soiling
Rectal exam
Predisposing Therapy Neuropsychological Effects Health Screening
Methotrexate (high-dose IV or IT); cytarabine (high-dose IV or IT); radiation impacting the brain; neurosurgery–brainNeurocognitive deficits (executive function, memory, attention, processing speed, etc.); learning deficits; diminished IQ; behavioral changeAssessment of educational and vocational progress
Formal neuropsychological evaluation

Psychosocial

Many childhood cancer survivors report reduced quality of life or other adverse psychosocial outcomes.

  • In a series of CNS malignancy survivors (n = 802) reported from the CCSS, adverse outcome in indicators of successful adult adaptation (educational attainment, income, employment, and marital status) were most likely in survivors who report neurocognitive dysfunction.[4]
  • Collectively, studies evaluating psychosocial outcomes among CNS tumor survivors indicate deficits in social competence that worsen over time.[61]
  • In a CCSS study that evaluated predictors of independent living status across diagnostic groups, adult survivors of childhood cancer with neurocognitive, psychological, or physical late effects were less likely to live independently as adults than were siblings in the control group.[35]

Childhood cancer survivors are also at risk of developing symptoms of psychological distress. In a longitudinal study of more than 4,500 survivors, subgroups of survivors were found to be at risk of developing persistent and increasing symptoms of anxiety and depression during a 16-year period. Survivors who reported pain and worsening health status were at the greatest risk of developing symptoms of anxiety, depression, and somatization over time.[62] Adult survivors of childhood cancer are also at risk of suicide ideation compared with siblings, with survivors of CNS tumors being most likely to report thoughts of suicide. In a CCSS study that evaluated the prevalence of recurrent suicidal ideation among 9,128 adult long-term survivors of childhood cancer, survivors were more likely to report late suicidal ideation (odds ratio [OR], 51.9; 95% CI, 51.5–2.5) and recurrent suicidal ideation (OR, 52.6; 95% CI, 51.8–3.8) compared with siblings.[63] History of seizure was associated with a twofold increased likelihood of suicide ideation in survivors.

The presence of chronic health conditions can also impact aspects of psychological health. In a study that evaluated psychological outcomes among long-term survivors treated with HSCT, 22% of survivors and 8% of sibling controls reported adverse outcomes. Somatic distress was the most prevalent condition and affected 15% of HSCT survivors, representing a threefold higher risk compared with siblings. HSCT survivors with severe or life-threatening health conditions and active chronic GVHD had a twofold increased risk of somatic distress.[64]

Incorporation of psychological screening into clinical visits for childhood cancer survivors may be valuable; however, limiting such evaluations to those returning to long-term follow-up clinics may result in a biased subsample of survivors with more difficulties, and precise prevalence rates may be difficult to establish. A review of behavioral, emotional, and social adjustment among survivors of childhood brain tumors illustrates this point, with the prevalence of psychological maladjustment ranging from 25% to 93%.[65] In a study of 101 adult cancer survivors of childhood cancer, psychological screening was performed during a routine annual evaluation at the survivorship clinic at the Dana Farber Cancer Institute. On the Symptom Checklist 90 Revised, 32 subjects had a positive screen (indicating psychological distress), and 14 subjects reported at least one suicidal symptom. Risk factors for psychological distress included subjects’ dissatisfaction with physical appearance, poor physical health, and treatment with cranial radiation. In this study, the instrument was shown to be feasible for use in the clinic visit setting because the psychological screening was completed in less than 30 minutes. In addition, completion of the instrument itself did not appear to cause distress in the survivors in 80% of cases.[66] These data support the feasibility and importance of consistent assessment of psychosocial distress in a medical clinic setting.

(Refer to the PDQ summary on Adjustment to Cancer: Anxiety and Distress for more information about psychological distress and cancer patients.)

Post-traumatic stress after childhood cancer

Despite the many stresses associated with the diagnosis of cancer and its treatment, studies have generally shown low levels of post-traumatic stress symptoms and post-traumatic stress disorder (PTSD) in children with cancer, typically no higher than those in healthy comparison children.[67] Patient and parent adaptive style are significant determinants of PTSD in the pediatric oncology setting.[68,69]

The prevalence of PTSD and post-traumatic stress symptoms has been reported in 15% to 20% of young adult survivors of childhood cancer, with estimates varying based on criteria used to define these conditions.[70]

  • Survivors with PTSD reported more psychological problems and negative beliefs about their illness and health status than did those without PTSD.[71,72]
  • A subset of adult survivors (9%) from the CCSS reported functional impairment and/or clinical distress in addition to the set of symptoms consistent with a full diagnosis of PTSD. This was significantly more prevalent in survivors than in sibling comparisons.[73] In this study, PTSD was significantly associated with being unmarried, having an annual income of less than $20,000, being unemployed, having a high school education or less, and being older than 30 years. Survivors who were treated with cranial radiation before age 4 years were at particularly high risk for PTSD. Intensive treatment was also associated with increased risk of full PTSD.

Because avoidance of places and persons associated with the cancer is part of PTSD, the syndrome may interfere with obtaining appropriate health care. Those with PTSD perceive greater current threats to their lives or the lives of their children. Other risk factors include poor family functioning, decreased social support, and noncancer stressors.[74]

Psychosocial outcomes among childhood, adolescent, and young adult cancer survivors

Most research on late effects after cancer has focused on individuals with a cancer manifestation during childhood. Little is known about the specific impact of a cancer diagnosis with an onset in adolescence or the impact of childhood cancer on adolescent and young adult psychosocial outcomes. The following studies describe psychosocial outcomes among these groups:

  • In 820 adult survivors of cancer diagnosed during adolescence (between ages 15 and 18 years), when compared with an age-matched sample from the general population and a control group of adults without cancer, female survivors of adolescent cancers achieved fewer developmental milestones in their psychosexual development, such as having their first boyfriend, or reached these milestones later. Male survivors were more likely to live with their parents than were same-sex controls. Adolescent cancer survivors were less likely to have ever married or have had children. Survivors were significantly older at their first marriage and at the birth of their first child than were their age-matched samples.[75]

    Survivors in this cohort were also significantly less satisfied with their general and health-related life than were people in a community-based control group. Impaired general and health-related life satisfaction were associated with somatic late effects, symptoms of depression and anxiety, and lower rates of posttraumatic growth.[76]

  • In a survey of 4,054 adolescent and young adult (AYA) cancer survivors and 345,592 respondents who had no history of cancer, AYA cancer survivors were more likely to smoke (26% vs. 18%), be obese (31% vs. 27%), and have chronic conditions such as cardiovascular disease (14% vs. 7%), hypertension (35% vs. 9%), asthma (15% vs. 8%), disability (36% vs. 18%), and poor mental health (20% vs. 10%). They were also less likely to receive medical care because of cost (24% vs. 15%).[77]
  • The CCSS evaluated outcomes of 2,979 adolescent survivors and 649 siblings of cancer survivors to determine the incidence of difficulty in six behavioral and social domains (depression/anxiety, being headstrong, attention deficit, peer conflict/social withdrawal, antisocial behaviors, and social competence).[78] Survivors were 1.5 times (99% CI, 1.1–2.1) more likely than were siblings to have symptoms of depression/anxiety and 1.7 times (99% CI, 1.3–2.2) more likely than were siblings to have antisocial behaviors. Scores in the depression/anxiety, attention deficit, and antisocial domains were significantly elevated in adolescents treated for leukemia or CNS tumors, compared with the scores in siblings. In addition, survivors of neuroblastoma had difficulty in the depression/anxiety and antisocial domains. CNS-directed treatments (cranial radiation and/or intrathecal methotrexate) were specific risk factors for adverse behavioral outcomes.

It should be noted that social withdrawal in adolescence was associated with adult obesity and physical inactivity.[79] As a result, these psychological problems may increase future risk for chronic health conditions and support the need to routinely screen and treat psychological problems after cancer therapy.

Because of the challenges experienced by adolescents and young adults at cancer diagnosis and during long-term follow-up, this group needs to have access to programs to address the unique psychosocial, educational, and vocational issues that impact their transition to survivorship.[80,81]

Refer to the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers for CNS and psychosocial late effects information, including risk factors, evaluation, and health counseling.

References

  1. Nathan PC, Patel SK, Dilley K, et al.: Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in survivors of childhood cancer: a report from the Children's Oncology Group. Arch Pediatr Adolesc Med 161 (8): 798-806, 2007. [PUBMED Abstract]
  2. Robinson KE, Kuttesch JF, Champion JE, et al.: A quantitative meta-analysis of neurocognitive sequelae in survivors of pediatric brain tumors. Pediatr Blood Cancer 55 (3): 525-31, 2010. [PUBMED Abstract]
  3. Reeves CB, Palmer SL, Reddick WE, et al.: Attention and memory functioning among pediatric patients with medulloblastoma. J Pediatr Psychol 31 (3): 272-80, 2006. [PUBMED Abstract]
  4. Ellenberg L, Liu Q, Gioia G, et al.: Neurocognitive status in long-term survivors of childhood CNS malignancies: a report from the Childhood Cancer Survivor Study. Neuropsychology 23 (6): 705-17, 2009. [PUBMED Abstract]
  5. Butler RW, Fairclough DL, Katz ER, et al.: Intellectual functioning and multi-dimensional attentional processes in long-term survivors of a central nervous system related pediatric malignancy. Life Sci 93 (17): 611-6, 2013. [PUBMED Abstract]
  6. Patel SK, Mullins WA, O'Neil SH, et al.: Neuropsychological differences between survivors of supratentorial and infratentorial brain tumours. J Intellect Disabil Res 55 (1): 30-40, 2011. [PUBMED Abstract]
  7. Krull KR, Khan RB, Ness KK, et al.: Symptoms of attention-deficit/hyperactivity disorder in long-term survivors of childhood leukemia. Pediatr Blood Cancer 57 (7): 1191-6, 2011. [PUBMED Abstract]
  8. Kahalley LS, Conklin HM, Tyc VL, et al.: ADHD and secondary ADHD criteria fail to identify many at-risk survivors of pediatric ALL and brain tumor. Pediatr Blood Cancer 57 (1): 110-8, 2011. [PUBMED Abstract]
  9. Reddick WE, Glass JO, Helton KJ, et al.: Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 26 (5): 1263-9, 2005. [PUBMED Abstract]
  10. Reimers TS, Ehrenfels S, Mortensen EL, et al.: Cognitive deficits in long-term survivors of childhood brain tumors: Identification of predictive factors. Med Pediatr Oncol 40 (1): 26-34, 2003. [PUBMED Abstract]
  11. Palmer SL, Goloubeva O, Reddick WE, et al.: Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol 19 (8): 2302-8, 2001. [PUBMED Abstract]
  12. Armstrong GT, Conklin HM, Huang S, et al.: Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol 13 (2): 223-34, 2011. [PUBMED Abstract]
  13. Di Pinto M, Conklin HM, Li C, et al.: Learning and memory following conformal radiation therapy for pediatric craniopharyngioma and low-grade glioma. Int J Radiat Oncol Biol Phys 84 (3): e363-9, 2012. [PUBMED Abstract]
  14. Ris MD, Walsh K, Wallace D, et al.: Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961. Pediatr Blood Cancer 60 (8): 1350-7, 2013. [PUBMED Abstract]
  15. Bowers DC, Liu Y, Leisenring W, et al.: Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 24 (33): 5277-82, 2006. [PUBMED Abstract]
  16. Mabbott DJ, Spiegler BJ, Greenberg ML, et al.: Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol 23 (10): 2256-63, 2005. [PUBMED Abstract]
  17. Brière ME, Scott JG, McNall-Knapp RY, et al.: Cognitive outcome in pediatric brain tumor survivors: delayed attention deficit at long-term follow-up. Pediatr Blood Cancer 50 (2): 337-40, 2008. [PUBMED Abstract]
  18. Edelstein K, Spiegler BJ, Fung S, et al.: Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes. Neuro Oncol 13 (5): 536-45, 2011. [PUBMED Abstract]
  19. Mulhern RK, Merchant TE, Gajjar A, et al.: Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 5 (7): 399-408, 2004. [PUBMED Abstract]
  20. Mulhern RK, White HA, Glass JO, et al.: Attentional functioning and white matter integrity among survivors of malignant brain tumors of childhood. J Int Neuropsychol Soc 10 (2): 180-9, 2004. [PUBMED Abstract]
  21. Reddick WE, White HA, Glass JO, et al.: Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors. Cancer 97 (10): 2512-9, 2003. [PUBMED Abstract]
  22. Brinkman TM, Reddick WE, Luxton J, et al.: Cerebral white matter integrity and executive function in adult survivors of childhood medulloblastoma. Neuro Oncol 14 (Suppl 4): iv25-36, 2012. [PUBMED Abstract]
  23. Zeller B, Tamnes CK, Kanellopoulos A, et al.: Reduced neuroanatomic volumes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 31 (17): 2078-85, 2013. [PUBMED Abstract]
  24. Jacola LM, Ashford JM, Reddick WE, et al.: The relationship between working memory and cerebral white matter volume in survivors of childhood brain tumors treated with conformal radiation therapy. J Neurooncol 119 (1): 197-205, 2014. [PUBMED Abstract]
  25. Palmer SL, Glass JO, Li Y, et al.: White matter integrity is associated with cognitive processing in patients treated for a posterior fossa brain tumor. Neuro Oncol 14 (9): 1185-93, 2012. [PUBMED Abstract]
  26. Ris MD, Packer R, Goldwein J, et al.: Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 19 (15): 3470-6, 2001. [PUBMED Abstract]
  27. Merchant TE, Conklin HM, Wu S, et al.: Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 27 (22): 3691-7, 2009. [PUBMED Abstract]
  28. Palmer SL, Armstrong C, Onar-Thomas A, et al.: Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. J Clin Oncol 31 (28): 3494-500, 2013. [PUBMED Abstract]
  29. Knight SJ, Conklin HM, Palmer SL, et al.: Working memory abilities among children treated for medulloblastoma: parent report and child performance. J Pediatr Psychol 39 (5): 501-11, 2014. [PUBMED Abstract]
  30. Schreiber JE, Gurney JG, Palmer SL, et al.: Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma. Neuro Oncol 16 (8): 1129-36, 2014. [PUBMED Abstract]
  31. Armstrong GT, Liu Q, Yasui Y, et al.: Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 101 (13): 946-58, 2009. [PUBMED Abstract]
  32. Brinkman TM, Palmer SL, Chen S, et al.: Parent-reported social outcomes after treatment for pediatric embryonal tumors: a prospective longitudinal study. J Clin Oncol 30 (33): 4134-40, 2012. [PUBMED Abstract]
  33. Moyer KH, Willard VW, Gross AM, et al.: The impact of attention on social functioning in survivors of pediatric acute lymphoblastic leukemia and brain tumors. Pediatr Blood Cancer 59 (7): 1290-5, 2012. [PUBMED Abstract]
  34. Mitby PA, Robison LL, Whitton JA, et al.: Utilization of special education services and educational attainment among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer 97 (4): 1115-26, 2003. [PUBMED Abstract]
  35. Kunin-Batson A, Kadan-Lottick N, Zhu L, et al.: Predictors of independent living status in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 57 (7): 1197-203, 2011. [PUBMED Abstract]
  36. Janson C, Leisenring W, Cox C, et al.: Predictors of marriage and divorce in adult survivors of childhood cancers: a report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev 18 (10): 2626-35, 2009. [PUBMED Abstract]
  37. Pui CH, Howard SC: Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 9 (3): 257-68, 2008. [PUBMED Abstract]
  38. Waber DP, Queally JT, Catania L, et al.: Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis. Pediatr Blood Cancer 58 (5): 758-65, 2012. [PUBMED Abstract]
  39. Krull KR, Brinkman TM, Li C, et al.: Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol 31 (35): 4407-15, 2013. [PUBMED Abstract]
  40. Reddick WE, Shan ZY, Glass JO, et al.: Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer 106 (4): 941-9, 2006. [PUBMED Abstract]
  41. Kadan-Lottick NS, Zeltzer LK, Liu Q, et al.: Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst 102 (12): 881-93, 2010. [PUBMED Abstract]
  42. Krull KR, Zhang N, Santucci A, et al.: Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation. Blood 122 (4): 550-3, 2013. [PUBMED Abstract]
  43. Spiegler BJ, Kennedy K, Maze R, et al.: Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 24 (24): 3858-64, 2006. [PUBMED Abstract]
  44. Campbell LK, Scaduto M, Sharp W, et al.: A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer 49 (1): 65-73, 2007. [PUBMED Abstract]
  45. Mennes M, Stiers P, Vandenbussche E, et al.: Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Pediatr Blood Cancer 44 (5): 478-86, 2005. [PUBMED Abstract]
  46. Jansen NC, Kingma A, Schuitema A, et al.: Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia. J Clin Oncol 26 (18): 3025-30, 2008. [PUBMED Abstract]
  47. Espy KA, Moore IM, Kaufmann PM, et al.: Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. J Pediatr Psychol 26 (1): 1-9, 2001 Jan-Feb. [PUBMED Abstract]
  48. Kaemingk KL, Carey ME, Moore IM, et al.: Math weaknesses in survivors of acute lymphoblastic leukemia compared to healthy children. Child Neuropsychol 10 (1): 14-23, 2004. [PUBMED Abstract]
  49. Buizer AI, de Sonneville LM, Veerman AJ: Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature. Pediatr Blood Cancer 52 (4): 447-54, 2009. [PUBMED Abstract]
  50. von der Weid N, Mosimann I, Hirt A, et al.: Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences. Eur J Cancer 39 (3): 359-65, 2003. [PUBMED Abstract]
  51. Conklin HM, Krull KR, Reddick WE, et al.: Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst 104 (18): 1386-95, 2012. [PUBMED Abstract]
  52. Halsey C, Buck G, Richards S, et al.: The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol 4: 42, 2011. [PUBMED Abstract]
  53. Armstrong GT, Reddick WE, Petersen RC, et al.: Evaluation of memory impairment in aging adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiotherapy. J Natl Cancer Inst 105 (12): 899-907, 2013. [PUBMED Abstract]
  54. Kadan-Lottick NS, Brouwers P, Breiger D, et al.: A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 114 (9): 1746-52, 2009. [PUBMED Abstract]
  55. Phipps S, Rai SN, Leung WH, et al.: Cognitive and academic consequences of stem-cell transplantation in children. J Clin Oncol 26 (12): 2027-33, 2008. [PUBMED Abstract]
  56. Shah AJ, Epport K, Azen C, et al.: Progressive declines in neurocognitive function among survivors of hematopoietic stem cell transplantation for pediatric hematologic malignancies. J Pediatr Hematol Oncol 30 (6): 411-8, 2008. [PUBMED Abstract]
  57. Anderson FS, Kunin-Batson AS, Perkins JL, et al.: White versus gray matter function as seen on neuropsychological testing following bone marrow transplant for acute leukemia in childhood. Neuropsychiatr Dis Treat 4 (1): 283-8, 2008. [PUBMED Abstract]
  58. Ness KK, Hudson MM, Pui CH, et al.: Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer 118 (3): 828-38, 2012. [PUBMED Abstract]
  59. Ness KK, Jones KE, Smith WA, et al.: Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. Arch Phys Med Rehabil 94 (8): 1451-7, 2013. [PUBMED Abstract]
  60. Goldsby RE, Liu Q, Nathan PC, et al.: Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 28 (2): 324-31, 2010. [PUBMED Abstract]
  61. Schulte F, Barrera M: Social competence in childhood brain tumor survivors: a comprehensive review. Support Care Cancer 18 (12): 1499-513, 2010. [PUBMED Abstract]
  62. Brinkman TM, Zhu L, Zeltzer LK, et al.: Longitudinal patterns of psychological distress in adult survivors of childhood cancer. Br J Cancer 109 (5): 1373-81, 2013. [PUBMED Abstract]
  63. Brinkman TM, Zhang N, Recklitis CJ, et al.: Suicide ideation and associated mortality in adult survivors of childhood cancer. Cancer 120 (2): 271-7, 2014. [PUBMED Abstract]
  64. Sun CL, Francisco L, Baker KS, et al.: Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood 118 (17): 4723-31, 2011. [PUBMED Abstract]
  65. Fuemmeler BF, Elkin TD, Mullins LL: Survivors of childhood brain tumors: behavioral, emotional, and social adjustment. Clin Psychol Rev 22 (4): 547-85, 2002. [PUBMED Abstract]
  66. Recklitis C, O'Leary T, Diller L: Utility of routine psychological screening in the childhood cancer survivor clinic. J Clin Oncol 21 (5): 787-92, 2003. [PUBMED Abstract]
  67. Phipps S, Klosky JL, Long A, et al.: Posttraumatic stress and psychological growth in children with cancer: has the traumatic impact of cancer been overestimated? J Clin Oncol 32 (7): 641-6, 2014. [PUBMED Abstract]
  68. Phipps S, Larson S, Long A, et al.: Adaptive style and symptoms of posttraumatic stress in children with cancer and their parents. J Pediatr Psychol 31 (3): 298-309, 2006. [PUBMED Abstract]
  69. Phipps S, Jurbergs N, Long A: Symptoms of post-traumatic stress in children with cancer: does personality trump health status? Psychooncology 18 (9): 992-1002, 2009. [PUBMED Abstract]
  70. Stuber ML, Meeske KA, Leisenring W, et al.: Defining medical posttraumatic stress among young adult survivors in the Childhood Cancer Survivor Study. Gen Hosp Psychiatry 33 (4): 347-53, 2011 Jul-Aug. [PUBMED Abstract]
  71. Rourke MT, Hobbie WL, Schwartz L, et al.: Posttraumatic stress disorder (PTSD) in young adult survivors of childhood cancer. Pediatr Blood Cancer 49 (2): 177-82, 2007. [PUBMED Abstract]
  72. Schwartz L, Drotar D: Posttraumatic stress and related impairment in survivors of childhood cancer in early adulthood compared to healthy peers. J Pediatr Psychol 31 (4): 356-66, 2006. [PUBMED Abstract]
  73. Stuber ML, Meeske KA, Krull KR, et al.: Prevalence and predictors of posttraumatic stress disorder in adult survivors of childhood cancer. Pediatrics 125 (5): e1124-34, 2010. [PUBMED Abstract]
  74. Hobbie WL, Stuber M, Meeske K, et al.: Symptoms of posttraumatic stress in young adult survivors of childhood cancer. J Clin Oncol 18 (24): 4060-6, 2000. [PUBMED Abstract]
  75. Dieluweit U, Debatin KM, Grabow D, et al.: Social outcomes of long-term survivors of adolescent cancer. Psychooncology 19 (12): 1277-84, 2010. [PUBMED Abstract]
  76. Seitz DC, Hagmann D, Besier T, et al.: Life satisfaction in adult survivors of cancer during adolescence: what contributes to the latter satisfaction with life? Qual Life Res 20 (2): 225-36, 2011. [PUBMED Abstract]
  77. Tai E, Buchanan N, Townsend J, et al.: Health status of adolescent and young adult cancer survivors. Cancer 118 (19): 4884-91, 2012. [PUBMED Abstract]
  78. Schultz KA, Ness KK, Whitton J, et al.: Behavioral and social outcomes in adolescent survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 25 (24): 3649-56, 2007. [PUBMED Abstract]
  79. Krull KR, Huang S, Gurney JG, et al.: Adolescent behavior and adult health status in childhood cancer survivors. J Cancer Surviv 4 (3): 210-7, 2010. [PUBMED Abstract]
  80. Freyer DR: Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. J Clin Oncol 28 (32): 4810-8, 2010. [PUBMED Abstract]
  81. Nathan PC, Hayes-Lattin B, Sisler JJ, et al.: Critical issues in transition and survivorship for adolescents and young adults with cancers. Cancer 117 (10 Suppl): 2335-41, 2011. [PUBMED Abstract]
  • Updated: December 17, 2014